Navigation Links
Alterations in Intestinal Serotonin in Irritable Bowel Syndrome and,Dyspepsia

ROCHESTER, MN, May 21, 2007-- Serotonin is a neurotransmitter that helps regulate intestinal functions. Mayo Clinic researchers set out to determine the role of serotonin in patients with IBS and dyspepsia. The study involved 48 females -- including individuals with IBS, individuals with dyspepsia, individuals with both IBS and dyspepsia, and healthy volunteers. Biopsies were obtained from the stomach and intestines of each patient and serotonin levels were measured. Researchers found that patients with dyspepsia had low levels of a serotonin reuptake transporter in their stomachs and high levels of a molecule that synthesizes serotonin in the small intestine.

"The results support the concept that functional disorders may be associated with altered serotonin signaling in different regions of the gut. If the data can be validated, it suggests it may someday be possible to make a diagnosis of functional disease by taking a biopsy," says Amy Foxx-Orenstein, D.O., a Mayo Clinic gastroenterologist and lead author of this study. "Mucosal markers for functional disorders might lead to earlier diagnosis and treatment, but further studies are needed."


Mayo Clinic
200 First St. S.W.
Rochester, MN 55905
(507) 284-2511

'"/>




Page: 1

Related medicine technology :

1. British Journal of Cancer Reports Preclinical Evidence of Positive Effect of Rice Bran on Intestinal Cancer
2. Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington, D.C.
3. New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
4. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
5. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
6. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
7. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
8. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
9. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
10. Fragile X, Down Syndromes Linked to Faulty Brain Communication, Stanford Researcher Finds
11. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
Post Your Comments:
(Date:5/15/2008)...Showed Acceptable Tolerability Profile, ... WOODCLIFF LAKE, N.J., May 15 /- The ...sylate (E7389) demonstrated activity in a,heavily ...ed or metastatic,breast cancer, according to resul...study also suggests that eribulin mesylate has a m...
(Date:5/15/2008)...ated in Blacks, Hispanics/Latinos, People ...SIPPANY, N.J., May 15 /- Daiichi Sank...he American Society of,Hypertension,s Twenty- Thir...ans demonstrated that the powerful combination dru...afely and effectively helped,patients across sever...
(Date:5/15/2008)... /- Ergonex Pharma today,announced th...(FDA) has,granted orphan drug designation to Tergu...tension (PAH). Terguride is currently being evalua..., "The FDA,s grant of orphan drug designation to ...evelopment program by offering regulatory,clinica...
(Date:5/15/2008)...or an Antiplatelet Therapy that, Combined, with As...f Plavix/Iscover and Aspirin, According to a N..., May 15 /- Decision Resources, one o...for pharmaceutical and,healthcare issues, finds th...vement in patient compared to Sanofi-Aventis/Brist...
Breaking Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 1Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 4Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 1Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 2ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 1ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 2Vioxx Settlement Announced 6028 1
..., 2007 - New data show the,investigational drug te...ted with Huntington,s disease (HD) up to 80 weeks ...ment in a 13-week trial.,These data suggest that t...educed chorea burden in long-term use., "These fin...nazine as maintenance therapy for U.S. patients wh...
...RE)--May 4, 2007 - New data from a,randomized, dou...ONE(R) (glatiramer acetate injection) along with t...um (Gd)-enhancing lesions,of the brain by 63 perce...tting multiple sclerosis (RRMS), as measured by,ma...receiving,COPAXONE(R) alone. Additionally, the nin...
Other Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:5/15/2008)...NG, China, May 15 /Xinhua-PRNewswire-FirstCall/ --...lletin Board: GTEC) ("Genesis" or,the "Company"), ...perations,in the People,s Republic of China, today...nded March 31, 2008, the Company,s third quarter o...m was filed for the quarter,with the U.S. Securiti...
(Date:5/15/2008)...nt safety in hospitals focus of 48 NQF-endorsed me.../ -- Recognizing that patient,safety remains a maj...ty,Forum (NQF) today endorsed 48 voluntary consens...of acute care hospitals, including measures,addres...revention and care,of venous thromboembolism., "I...
(Date:5/15/2008)...ab injections every 3 months a more convenient re...Y, May 15 (HealthDay News) -- The drug ustekinumab... long-term treatment for moderate-to-severe psoria...of The Lancet . , Ustekinumab works by binding...une system that mediate inflammatory reactions in ...
(Date:5/15/2008)...TON, D.C. -- May 15, 2008 -- The Society for Card...day announced that it will hold its 2009 Annual Sc..., Las Vegas. The focused, collegial interventional...r early March meeting time beginning in 2010. , ...he premier interventional cardiology meeting of th...
Breaking Medicine News(10 mins):Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 2Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 4Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 5Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2
...umber of bus drivers and conductors in India are b...t of the bus conductor Ravindra Kamble (34). //Sta...ctors in the last one year have been tested positi...mme was started by General Manager SS Kshatriya in...
...ia's largest biotechnology firm, has made a paradi... innovation to drive its future growth aggressivel...s API (active pharmaceutical ingredients) manufact...loping a robust pipeline of new molecules. "We be...
...n accused of wasting over ?500m associated with ov...at John Hemming// who cited government figures on ...her added that once the drugs lost their patent, t... prices. The Birmingham Yardley MP blamed the hea...
...s from Denmark, published on bmj.com in February, ...s on a risehas caused a growing concern among doct...e of 22% from 1995 to 2004. They noted that this w... 20-40, where there was a 51% increase in early de...
Other Medicine News:Health News:Biocon To Shift Focus On Innovation To Accelerate Growth 2Health News:More Than ?500m Wasted On Drugs; MP Blames NH 2Health News:Concern Over The Rise In Preterm Deliveries 2
A sturdy, robust stool. Gas operated height adjustment for convenience.
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box.
Viscoelastic Cannula, 23 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box.
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box.
Medicine Products: